BioMark SSAT1 LIQUID BIOPSY ASSAY
BioMark’s initial assay detects SSAT1, an enzyme with elevated levels in numerous cancers, using an FDA approved drug. The assay targets a well researched and understood metabolic pathway. BioMark is amongst a unique group of companies that uses a safe therapeutic agent for diagnostic indication. This assay (SSAT1) can be used as a non-invasive, cost effective red alert tool for physicians globally.
BioMark has completed a comprehensive set of trial and is currently assembling a submission package to Health Canada for market approval for this test which physicians can use as a screening test for Lung and Breast Cancer and help to assess the need for more definitive imaging or other molecular test.
There is compelling scientific evidence to suggest that the SSAT1 Assay can be expanded for Glioblastoma (GBM), Gastrointestinal, Prostate and Head and Neck Cancers.